Over the past 2 years, we had the opportunity to participate in an annual cross-cultural exchange that has broadened our horizons. Xi’an, the ancient capital of China and home of the Terracotta warriors, is a sprawling megapolis similar to Los Angeles. In the southern suburb of Huxian, US trained pulmonary, neurosurgical, and critical care physicians from Cooper University Hospital and Morehouse School of Medicine partnered with physicians of Ji-Ren Teaching Hospital to deliver a Chinese Medical Association accredited continuing medical education conference. The conference agenda included a variety of pulmonary and critical care topics highlighting sepsis, neurovascular disease, and lung cancer screening and diagnosis. We also provided a hands-on workshop for point of care ultrasound, and, in return, received education about Chinese medicine.
We found our hosts appreciative and hospitable, and they treated us with the highest level of respect (the cornerstone of Chinese culture). The audience was receptive and very interested in learning. However, while we were impressed with their rapid growth and interest in incorporating western medicine into their daily practice, it was impossible to overlook the major pulmonary health-care concerns threatening their communities. Tobacco use was omnipresent, and the haze of air pollution made the sky a constant shade of grey. In both public and private spaces, powerful echoes of a once familiar America resonated, and they served to underscore the obstacles the Chinese medical community now faces in caring for their country’s pulmonary health.
An Old, Familiar Foe
The China National Tobacco Corporation (CNTC) is the largest tobacco company in the world, as well as China’s most profitable state-owned enterprise (Pratt, A, et al. WHO Report. 2017. ISBN 9789290617907 [http://www.wpro.who.int/china/publications/2017_china_tobacco_control_report_en_web_final.pdf?ua=1]). As such, the CNTC controls every aspect of its production and supply chain with the force of the federal government and also exerts heavy influence over regulatory policy. It controls about 98% of domestic crop production and manages to price cigarettes just short of one American dollar per pack, yet contributes about $170 billion annually to the government (Rich, et al. Nicotine Tob Res. 2012;14[3]:258). This accounted for nearly 7% of total governmental revenue in 2015 (Pratt, 2017).
To date, nearly 44% of the world’s cigarettes are manufactured and consumed in China (Pratt 2017, Rich 2012). In 2015, more than 315 million Chinese adults were daily smokers, or about 28% of the adult population and nearly half of all men (Pratt, 2017). This is about double the proportion of US smokers (about 15.1%) and more than eight times the 36.5 million daily smokers in the United States (CDC Online Tobacco Use Report, 2016 [https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/]). However, to visit China is not only to know a love for tobacco, but also an overwhelming guest and gift culture. Gift giving and hospitality is central to the Chinese identity, from business meetings to afternoon tea. Given their economy and such rich supply, people gift cigarettes to one another at all times for nearly any occasion. Unfortunately, tobacco smoke in China is as inescapable as its health consequences.
The direct effects of smoking on China’s pulmonary health have been catastrophic. Cancers of the lung and bronchus constitute their most common malignancy across both sexes, accounting for the majority of the annual 4.3 million new cancer diagnoses (Chen et al. CA Cancer J Clin. 2016;66[2]:115). In Chinese men, lung cancer is the second most common cancer before the age of 60, and over the age of 75, it is the most common malignancy and also accounts for the majority of that group’s cancer mortality. Women fare only slightly better, with breast cancer being their most common malignancy, but with lung cancer remaining the most pervasive across all age groups, and, by far, the most deadly (Chen, 2016). All told, of the projected 2.8 million cancer deaths occurring in 2015 in China, 21% were directly a result of lung cancer.
Likewise, COPD also threatens China. The Global Burden of Disease study conducted in 2004 demonstrated that nearly 3 million people die of COPD each year. Chinese adults over the age of 40 had an overall prevalence of COPD of 9% for the last decade, though this may be higher given the high rate of underdiagnosis in rural China (Fang X, et al. Chest. 2011;139[4]:920). After 2004, the Chinese Ministry of Health affirmed that COPD was the fourth leading cause of mortality in urban areas, but third in rural ones (Fang, 2011). When investigators analyzed deaths secondary to cor pulmonale coexisting with COPD, they found COPD-related mortality increased to 179.9 for men and 141.3 for women per 100,000 persons, which is about double the COPD mortality for other countries in the Asian-Pacific region (Reilly K, et al. Am J Epidemiol. 2008;167[8]:998).
Both cancer and COPD in China disproportionately affect those in rural areas and with lower socioeconomic status, with smoking being the most potent causative exposure. On average, the annual direct and indirect per-patient cost of treating COPD amounted to about $2,000, comprising about 40% of a family’s total annual income (Fang, 2011). The cost of treating malignancy is even more expensive, but the higher likelihood of death results in an additional 10% to 20% reduction of family income when a working family member dies (Pratt, 2016). Taken together, and especially since rural Chinese citizens spend close to 20% of their income on tobacco products, the pulmonary health consequences of smoking are a significant driver of both health and economic inequality.
The Air We Breathe
Air pollution comprises a second pulmonary insult to China’s health. The International Agency for Research on Cancer designated particulate matter (PM) as a class I carcinogen (Kurt O, et al. Curr Opin Pulm Med. 2016;22[2]:138). PM forms from combustion of bio-mass fuel, as well as from dust storms or construction. Once particulates are smaller than 2.5 microns (PM2.5), they cause substantial harm to the pulmonary microenvironment. Guo and colleagues demonstrated markedly increased lung cancer risks associated with spatial mapping of ozone and PM2.5 concentrations (Guo Y, et al. Environ Res. 2016;144;60). PM2.5 also doubles the odds of contracting COPD in nonsmoking adults, conferring as much as a three-fold risk of contracting the disease in nonsmoking women (Fang, 2011).
Apart from causing pulmonary disease, studies also implicate air pollution as frequently causing exacerbations of existing disease. One study found an incremental increase in ED visits for respiratory illnesses for every 10 µg/m3 above the median PM2.5 level (Xu, et al. PLoS One. 2016;11(4): e0153099). In 2013, 83% of Chinese lived in places where PM2.5 levels exceeded China’s own ambient air standard. In this cohort, elevated PM2.5 levels contributed directly to 300,000 premature deaths from lung cancer and COPD, with PM2.5 causing 1.2 million premature deaths overall (Liu J, et al. Sci Total Environ. 2016;568;1253).
Moving Forward
The Chinese have few illusions about these pulmonary concerns, and they are making progress. The government recently introduced stricter smoking controls in Beijing and Shanghai and continues to explore ways to decrease emissions. President Xi has put forward strong initiatives to improve the health of the Chinese. However, the nation is trying to balance its national priorities in the context of a fluid, and, at times, perilous geopolitical climate. In some ways, their position is not too dissimilar from the US geopolitical and health-care situation of the 1970s. While challenging, the issue of Chinese health care should not overshadow the remarkable resources or the truly remarkable culture of their people. Friendship, cooperation, the reduction of suffering: these are ideals where all clinicians find common ground, regardless of nationality.
Dr. Mackay is Chief Fellow of Critical Care Medicine, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, New Jersey; Dr. Flenaugh is Associate Professor of Medicine, Division Chief of Pulmonary and Critical Care Medicine, Director of Advance Diagnostic and Interventional Pulmonary, Morehouse School of Medicine, Atlanta, Georgia.
Editor’s Note
This excellent, up-close Pulmonary Perspective details observations of Drs. Mackay and Flenaugh as they have participated in cross-cultural exchanges in
China with realization of the many obstacles to good pulmonary health for the Chinese population, obstacles including tobacco use, COPD, and air pollution. We appreciate their bringing these observations to the forefront.The American College of Chest Physicians, likewise concerned about pulmonary health in China, has approached the problem on a different front, working closely with partners, such as the Chinese Thoracic Society, the Chinese Association of Chest Physicians, and the Chinese Medical Doctor Association, to implement China’s first ever fellowship program offering standardized training in PCCM for Chinese physicians. Read more at http://www.mdedge.com/chestphysician/article/131179/society-news/pccm-endorsed-pilot-subspecialty-chinese-national-health.
Nitin Puri, MD, FCCP, is the section editor of Pulmonary Perspectives.